Compare LAKE & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAKE | CRBU |
|---|---|---|
| Founded | 1982 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.0M | 145.8M |
| IPO Year | 2013 | 2021 |
| Metric | LAKE | CRBU |
|---|---|---|
| Price | $12.05 | $1.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $15.33 | $10.75 |
| AVG Volume (30 Days) | 54.0K | ★ 1.7M |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $192,648,000.00 | N/A |
| Revenue This Year | $10.88 | $1.63 |
| Revenue Next Year | $10.71 | $10.93 |
| P/E Ratio | $297.00 | ★ N/A |
| Revenue Growth | ★ 15.21 | N/A |
| 52 Week Low | $7.15 | $1.38 |
| 52 Week High | $18.00 | $3.53 |
| Indicator | LAKE | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 61.99 | 38.54 |
| Support Level | $8.93 | $1.39 |
| Resistance Level | $11.96 | $1.77 |
| Average True Range (ATR) | 0.42 | 0.08 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 87.86 | 32.60 |
Lakeland Industries Inc manufactures and sells safety garments and accessories for the industrial protective clothing market. Its product segments include Disposables, Chemicals, Fire, Gloves, High Visibility, High-Performance Wear, and Wovens. Its customers include integrated oil, chemical/petrochemical, utilities, automobile, steel, glass, construction, smelting, munition plants, janitorial, pharmaceutical, and mortuaries, as well as scientific and medical laboratories. Its geographical segments include the United States, Latin America, Canada, Asia, Mexico, Europe, and Other Foreign. It generates the majority of its revenue from the United States.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.